Clinical Trials
38
Active:0
Completed:14
Trial Phases
4 Phases
Phase 1:16
Phase 2:7
Phase 3:10
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (34 trials with phase data)• Click on a phase to view related trials
Phase 1
16 (47.1%)Phase 3
10 (29.4%)Phase 2
7 (20.6%)Phase 4
1 (2.9%)An Open Clinical Trial of the Safety and Efficacy of the Drug Fluorothiazinone, 300 Mg Tablets with the Participation of Adult Patients with Chronic Bacterial Cystitis"
Phase 3
Not yet recruiting
- Conditions
- P. AeruginosaBaumanniiKlebsiella PneumoniaE.coli InfectionsEnterococcus Faecalis InfectionChronic Bacterial Cystitis
- Interventions
- Drug: Fluorothiazinone, tablets 300 mg
- First Posted Date
- 2025-02-07
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- Target Recruit Count
- 280
- Registration Number
- NCT06815549
Study of the Drug B11-FC (Botulism Treatment)
Phase 1
Not yet recruiting
- Conditions
- Botulism
- Interventions
- First Posted Date
- 2024-08-30
- Last Posted Date
- 2024-08-30
- Lead Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- Target Recruit Count
- 40
- Registration Number
- NCT06580236
The Surveillance Clinical Study of Rickettsiosis
Recruiting
- Conditions
- Rickettsiosis
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- Target Recruit Count
- 100
- Registration Number
- NCT06162975
- Locations
- 🇷🇺
Altai Republic Center for HIV prophylaxis and treatment, Gorno-Altaïsk, Altai Republic, Russian Federation
Clinical Trial to Study the Efficacy and Safety of Fluorothiazinone (N.F. Gamaleya NRCEM) in Prophylaxis of Nosocomial Bacterial Infections With Participation of Patients on MV
Phase 2
Recruiting
- Conditions
- Gram Negative PneumoniaGram-Negative Bacterial InfectionsBacteremia Caused by Gram-Negative Bacteria
- Interventions
- Other: PlaceboDrug: Fluorothiazinone, tablets 300 mg at a dose of 2400 mg/day
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- Target Recruit Count
- 234
- Registration Number
- NCT06135350
- Locations
- 🇷🇺
State Budgetary Healthcare Institution of Moscow City Clinical Hospital No. 1 named after N.I. Pirogov of the Moscow Department of Health (State Clinical Hospital No. 1 named after N.I. Pirogov), Moscow, Russian Federation
🇷🇺City Clinical Hospital No. 24 of the Moscow City Department of Health, Moscow, Russian Federation
An Open-label Study of the Safety and Pharmacokinetics of the TGKP
Phase 1
Not yet recruiting
- Conditions
- Acute Respiratory Distress Syndrome (ARDS)
- Interventions
- Drug: Glycolic acid tetrasubstituted piceatannol (TGKP)
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- Target Recruit Count
- 25
- Registration Number
- NCT06127381
- Prev
- 1
- 2
- 3
- 4
- 5
- 8
- Next
News
No news found